• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Heteroaromatic compounds Heteroaromatic compounds
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Heteroaromatic compounds

Recent Advances in the Application of (S)-1-(thiophen-2-yl)ethanol (CAS 27948-39-6) in Chemical Biology and Pharmaceutical Research

The chiral compound (S)-1-(thiophen-2-yl)ethanol (CAS 27948-39-6) has recently gained significant attention in chemical biology and pharmaceutical research due to its versatile applications as a key intermediate in drug synthesis and its potential biological activities. This research brief synthesizes the latest findings regarding this compound, focusing on its synthetic methodologies, pharmacological properties, and emerging applications in medicinal chemistry.

Recent studies have demonstrated improved synthetic routes for (S)-1-(thiophen-2-yl)ethanol with enhanced enantioselectivity and yield. A 2023 publication in the Journal of Organic Chemistry reported a novel biocatalytic approach using engineered ketoreductases that achieved >99% ee with 92% yield under mild reaction conditions. This advancement addresses previous challenges in the stereoselective synthesis of this important building block.

In pharmacological research, (S)-1-(thiophen-2-yl)ethanol has shown promise as a precursor for novel antiviral agents. A 2024 study published in Bioorganic & Medicinal Chemistry Letters described its incorporation into thiophene-containing nucleoside analogs that exhibited potent activity against RNA viruses, with EC50 values in the low micromolar range. The stereochemistry at the chiral center was found to be critical for antiviral potency, with the (S)-enantiomer showing 10-15 fold greater activity than its (R)-counterpart.

The compound's mechanism of action in various biological systems has been further elucidated through recent structural biology studies. X-ray crystallography data published in early 2024 revealed that (S)-1-(thiophen-2-yl)ethanol derivatives can bind to allosteric sites on certain kinase targets, inducing conformational changes that modulate enzymatic activity. This finding opens new possibilities for developing selective kinase inhibitors with reduced off-target effects.

From a drug delivery perspective, innovative formulations incorporating (S)-1-(thiophen-2-yl)ethanol have been developed to improve pharmacokinetic properties. A recent patent application (WO2023/189234) describes prodrug derivatives that significantly enhance oral bioavailability while maintaining the parent compound's therapeutic effects. These advances address previous limitations in the clinical translation of thiophene-based therapeutics.

Ongoing clinical trials are investigating (S)-1-(thiophen-2-yl)ethanol derivatives for various indications. Phase I results for a novel anti-inflammatory agent (TPE-201) derived from this scaffold demonstrated favorable safety profiles and preliminary efficacy in autoimmune disease models. The compound's unique ability to modulate Th17 cell differentiation without general immunosuppression makes it particularly attractive for chronic inflammatory conditions.

In conclusion, (S)-1-(thiophen-2-yl)ethanol (CAS 27948-39-6) continues to emerge as a valuable scaffold in pharmaceutical development. Recent advances in its synthesis, mechanistic understanding, and therapeutic applications position this compound as a promising candidate for multiple drug discovery programs. Future research directions may focus on expanding its utility in targeted therapies and exploring combination regimens with existing treatments.

• 155187-89-6(Thiophene, 2-(1-ethoxyethyl)-)
• 5331-62-4(2-thien-2-ylpropan-2-ol)
• 78002-44-5(1-(Thiophen-2-yl)ethanol)
• 23229-69-8(1-(thiophen-2-yl)propan-1-ol)
• 1665-39-0(2-Thiophenemethanol, 5-methyl-a-phenyl-)
• 6973-84-8(2-Thiophenemethanol, a-2-thienyl-)
• 2309-47-9(1-(thiophen-2-yl)ethan-1-ol)
• 86527-10-8((R)-1-(Thiophen-2-yl)ethanol)
• 556801-67-3(1,3-Propanediol, 1-(2-thienyl)-, (1S)-)
• 132706-15-1(1-(5-methylthiophen-2-yl)propan-1-ol)